3-deazaneplanocin A (DZNep) is the first nonspecific EZH2 inhibitor that has been widely used and induces significant antitumor activity in various cancer types, resulting into inhibition of PRC2 and removal of H3K27me3 marks62. The gene discussed is EZH2; the disease is cancer.